




(주)휴먼 임상시험센터

Human Skin Clinical Trials Center

Clinical Trial Report



NEXUS PHARMA CO., LTD.

Test product

GLUTANEX Glow Sun Cream Light

Report No.

HM-250520-IR-0052-27

Submission Date

June 04, 2025



1516~1517ho, 62, Digital-ro 31-gil, Guro-gu,
Seoul, Republic of Korea
Tel. 070-5222-9663
(Inquiry for examination, Extension number 1)
Fax. 070-7500-9650
E-mail. skin@humantest.co.kr

TEST REPORT CERTIFICATION

Certification Code: HM-250520-IR-0052-CD-27 Receipt Date: April 23, 2025

Client: NEXUS PHARMA CO., LTD. Test Completion Date: May 22, 2025

Representative: Seungje Sung

Address: 6F, 71, Gonghang-daero 45-gil, Gangseo-gu, Seoul, Republic of Korea

Product: GLUTANEX Glow Sun Cream Light

Test Result			
Test Item	Inspection Standard	Result	Irritation Evaluation
Primary skin irritation test	*Remark	0.00	No irritation (Excellent)

Test Methods: After wiping the subject's test area with 70% ethanol and drying it, load of the test product in Finn Chamber® and attach it on the skin for 24 hours. The dermatologist assessed whether skin irritation was present at 30 minutes and 24 hours after patch removal.

Skin Irritation Index	Irritation Evaluation
0.00 ~ 0.25	No irritation (Excellent)
0.26 ~ 1.00	Mild irritation (Good)
1.01 ~ 2.50	Medium irritation (Bad)
2.51 ~ 4.00	Strong irritation (Very Bad)

Authentication

GLUTANEX Glow Sun Cream Light	
Study item	Primary skin irritation test

This study requested by NEXUS PHARMA CO., LTD. was conducted in accordance with the GCP (Good Clinical Practice), guidelines of MFDS (Ministry of Food and Drug Safety) and the Standard operation procedure of Human Co., Ltd. Skin Clinical Trial Center. The results are reported as follows.

June 04, 2025

President	Human Co., Ltd. Skin Clinical Trial Center	Huijeong Jeong	
Principal Investigator	Human Co., Ltd. Skin Clinical Trial Center	Wonkyu Hong, M.D., Ph.D.	

Contents

TEST REPORT CERTIFICATION	1
Contents	3
Information of the Study Request	4
Quality Assurance Statement	5
Report Summary	7
1. Study purpose.....	8
2. Investigational product and Ingredients	8
3. Subjects.....	10
3.1. Inclusion criteria	10
3.2. Exclusion criteria	10
3.3. Number of subjects.....	10
3.4. Criteria for premature withdrawal and dropout from the study	11
3.5. Regulations on Human Application Tests for Test Subjects	11
3.6. Subject Obligations	12
3.7. Confidentiality of Information and Fiduciary Duty	12
4. Methodology.....	13
4.1. Materials to conduct the study.....	13
4.2. Test method and test site	13
4.3. Evaluation procedure.....	13
4.4. Determination of irritation	14
4.5. Evaluation of skin adverse event.....	14
5. Results.....	15
5.1. Results of skin primary irritation test.....	15
5.2. Evaluation result of skin adverse event	15
6. Conclusion	16
7. References.....	17
8. Appendix	18
Institutional Assessment Report	24
Research Resume	25
List of publications	35

Information of the Study Request

Study Title	Primary skin irritation test of GLUTANEX Glow Sun Cream Light	
Study Code	HM-250520-IR-0052-27	
IRB Code	HM-IRB-IR0052-27	
Study Period	May 20, 2025 ~ May 22, 2025	
Report Date	June 04, 2025	
Clinical Trial Center	Test Center	Human Co., Ltd. Skin Clinical Trial Center
	Address	1516~1517ho, 62, Digital 31-gil, Guro-gu, Seoul, Republic of Korea
	President	Huijeong Jeong
	Principal Investigator	Wonkyu Hong / Dermatologist
	Investigator	Jiyeon Yun Researcher
	Tel.	+82-70-4680-0158
	E-mail	yjy@humantest.co.kr
Sponsor	Name	NEXUS PHARMA CO., LTD.
	Address	6F, 71, Gonghang-daero 45-gil, Gangseo-gu, Seoul, Republic of Korea
	President	Seungje Sung
	Monitor	Yookyung Hyun
	Tel.	+82-2-2658-2408
	E-mail	ykhyun@nexus-pharma.com

Quality Assurance Statement

Study Title	Primary skin irritation test of GLUTANEX Glow Sun Cream Light
Study Code	HM-250520-IR-0052-27
IRB Code	HM-IRB-IR0052-27
Study Period	May 20, 2025 ~ May 22, 2025

A Clinical trial for humans was conducted accurately in accordance with the test protocol agreed 20on with NEXUS PHARMA CO., LTD., GCP (Good Clinical Practice), MFDS (Ministry of Food and Drug Safety) guidelines, and the Standard Operating Procedures (SOP) of Human Co., Ltd. Skin Clinical Trial Center. We confirm that the results have been faithfully reflected. All result obtained during the study period have been faithfully reflected in this report, and it is certified that all procedures of this clinical trial were inspected under the supervision of quality assurance and received finally approval from principal investigator, as detailed below.

Classification	Inspection Items	Inspection Date	Status of Approval
Equipment and Facilities	Routine Inspection of Equipment	2025. 04. 24	Approval
	Document and Sample Storage Facility		Approval
	Laboratory Structure		Approval
Study Plan	Study Protocol	2025. 04. 23	Approval
	IRB Approval	2025. 04. 24	Approval
	Preparation of Test Product Information	2025. 05. 19	Approval
	Subject recruitment		Approval
Study Process	Study procedure and data analysis	2025. 05. 20 ~ 2025. 05. 22	Approval
	IRB Study completion certification	2025. 05. 29	Approval
Report	Finial Reported Date(Korea)	2025. 05. 30	Approval
	Finial Reported Date(English)	2025. 06. 04	Approval
	Documents Storage	2025. 05. 30	Approval

June 04, 2025

Principal Investigator: Wonkyu Hong



Quality Assurance: Hongsuk Kim



Report Summary

Study Title	Primary skin irritation test of GLUTANEX Glow Sun Cream Light													
Clinical Trial Center	Human Co., Ltd. Skin Clinical Trial Center	Sponsor	NEXUS PHARMA CO., LTD.											
Study Code	HM-250520-IR-0052-27	IRB Code	HM-IRB-IR0052-27											
Study Period	May 20, 2025 ~ May 22, 2025													
Purpose	To evaluate the safety in terms of primary skin irritation on humans of [GLUTANEX Glow Sun Cream Light].													
Results	<p>1. Subjects Final Number of Subject (Average age): 34 females (56.79 yrs)</p> <p>2. Results</p> <table border="1"> <thead> <tr> <th>No.*</th> <th>Name of the product</th> <th>Skin Irritation Index</th> <th>Concentration</th> <th>Irritation Evaluation</th> </tr> </thead> <tbody> <tr> <td>C-7</td> <td>GLUTANEX Glow Sun Cream Light</td> <td>0.00</td> <td>As is</td> <td>No irritation (Excellent)</td> </tr> </tbody> </table> <p><i>*Location on the application of the product</i></p>				No.*	Name of the product	Skin Irritation Index	Concentration	Irritation Evaluation	C-7	GLUTANEX Glow Sun Cream Light	0.00	As is	No irritation (Excellent)
No.*	Name of the product	Skin Irritation Index	Concentration	Irritation Evaluation										
C-7	GLUTANEX Glow Sun Cream Light	0.00	As is	No irritation (Excellent)										
Conclusion	As result of primary skin irritation test, the [GLUTANEX Glow Sun Cream Light] requested by [NEXUS PHARMA CO., LTD.] is considered a non-irritating product.													

1. Study purpose

Primary irritation human application test using a skin patch was performed to evaluate the safety of the [GLUTANEX Glow Sun Cream Light] requested by NEXUS PHARMA CO., LTD. by measuring the irritation index on the human skin.

2. Investigational product and Ingredients

Table 1. Investigational product

Name	GLUTANEX Glow Sun Cream Light
Formulation	cream
Identification code	250502-P-01
Quantity supplied	1ea
Date of receipt	2025. 05. 02
Analytical control	Sponsor should provide information about the test product. Chemical analysis in order to confirm the stability and physical properties of test products will not be provided.
Storage	Investigational product is stored for 180 days from the date of issuance of the test result report at the temperature range of 5°C ~ 25°C away from heat and direct sunlight. Investigational product will be discarded if there is no specific request from the sponsor after the expiration of this storage period.
Application area	Back
Dosage	20 μ l
Patch frequency	once

Table 2. Test Sample All Ingredients**GLUTANEX Glow Sun Cream Light**

Water, Dibutyl Adipate, Propanediol, Diethylamino Hydroxybenzoyl Hexyl Benzoate, Polymethylsilsesquioxane, Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, Ethylhexyl Triazone, Caprylyl Methicone, Methylene Bis-benzotriazolyl Tetramethylbutylphenol, Butyloctyl Salicylate, Niacinamide, Glycerin, 1,2-Hexanediol, Pentylene Glycol, Polyglyceryl-3 Methylglucose Distearate, Behenyl Alcohol, Polyglyceryl-10 Laurate, Decyl Glucoside, Poly C10-30 Alkyl Acrylate, Tromethamine, Sodium Stearoyl Glutamate, Carbomer, Xylitol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, C18-21 Alkane, Stearyl Heptanoate, Ammonium Acryloyldimethyltaurate/VP Copolymer, Glutathione, Hydrogenated Lecithin, Methylpropanediol, Ethylhexylglycerin, Adenosine, Trisodium Ethylenediamine Disuccinate, Polyether-1, Xanthan Gum, Butylene Glycol, Sodium DNA, Coffea Arabica (Coffee) Seed Extract, Eucalyptus Globulus Leaf Extract, Laurus Nobilis Leaf Extract, Theobroma Cacao (Cocoa) Seed Extract, Dimethylsilanol Hyaluronate, Hydrolyzed Hyaluronic Acid, Hydrolyzed Sodium Hyaluronate, Centella Asiatica Extract, Centella Asiatica Leaf Extract, Centella Asiatica Root Extract, Hyaluronic Acid, Pinus Pinaster Bark Extract, Potassium Hyaluronate, Sodium Hyaluronate, Hydroxypropyltrimonium Hyaluronate, Sodium Hyaluronate Crosspolymer, Sodium Hyaluronate Dimethylsilanol, Tocopherol, Sodium Acetylated Hyaluronate, Asiatic Acid, Asiaticoside, Madecassic Acid, Madecassoside

3. Subjects

3.1. Inclusion criteria

- Male and female adults over the age 20 years old
- Subjects who signed consent form voluntarily after being sufficiently informed regarding the objectives of study and all related contents
- Subjects who are healthy without acute and chronic diseases including skin disorders
- Subjects who can be observed and traced throughout the entire study period

3.2. Exclusion criteria

- Subjects who is pregnant or breast-feeding
- Subject who has psychiatric disease and infectious skin disease
- Subject who has skin lesion on the test site such as moles, pimples, erythema, scalds (burns), hemotelangiosis, and scars
- Subject who has atopic skin disease
- Subject who has used skin ointment containing steroid on the test site for more than one month
- Subjects who have sensitive and hypersensitive skin
- Subject who has irritation history or allergy to adhesive tape
- Subject who has been part of the same clinical trial within the past 3 months
- Subject who is on contraceptive, anti-histamine and anti-inflammatory prescriptions
- Subject who has cosmetics or sunlight allergies
- Employee in this clinical trial center
- Anyone who is considered non-qualified by the investigator

3.3. Number of subjects

This study was conducted in compliance with the "Regulations on Functional Cosmetic Examination [Annex 1] Toxicity Test Method Section 7 (1) Human patch test method" by the MFDS (Ministry of Food and Drug Safety).

The results were calculated by obtaining the valid data from a minimum of 30 subjects.

3.4. Criteria for premature withdrawal and dropout from the study

The subjects who participating in this study can withdraw from the clinical trial any time, and the investigator can eliminate subjects from this test and exclude the data on the subject from the test result evaluation in the event of occurrence of one or more of the following reasons. When a subject is withdrawn, the investigator shall specify the corresponding reason and records other relevant matters to report to the principal investigator.

- (1) Voluntary withdrawal by the subject
- (2) Violation of the protocol
- (3) Occurrence of adverse event or seriously adverse event on the test site of a subject
- (4) Failure to follow up on the subject
- (5) Others

3.5. Regulations on Human Application Tests for Test Subjects

This human application test was carried out in accordance with the spirit of the Declaration of Helsinki and the GCP Guidelines to protect the rights, safety, and welfare of test subjects in the first place. The investigator faithfully implemented the following to ensure the safety of the test subjects.

- (1) During the test, the principal investigator and the examiner shall do their best to ensure the safety of the test subjects, and in the event of an adverse reaction, take prompt and appropriate measures to minimize the reaction.
- (2) If a test subject reports skin irritation or adverse reaction due to the test product during the trial, wipe off the used test product immediately, and if the symptoms do not improve, receive dermatological evaluation and appropriate treatment by the principal investigator.
- (3) If an adverse reaction occurs despite the normal course of the test, appropriate dermatological evaluation and treatment should be conducted.
- (4) In the event of any other abnormal skin reactions, the principal investigator and the investigator shall take appropriate measures along with the dermatological evaluation, and record the case and situation in detail.

3.6. Subject Obligations

- Comply with all inspection schedules during the trial period.
- Ensure that all symptoms that occur during the trial period are reported in detail and thoroughly.
- During this examination period, all materials such as questions and questionnaires of the examiner must be filled out sincerely and honestly.

3.7. Confidentiality of Information and Fiduciary Duty

- The confidentiality of the test subjects participating in this trial will be guaranteed. However, test data may be used for medical, academic research, or marketing purposes to the extent that the subject's identity is not revealed.
- Subjects must keep confidential information obtained through this test until the end of the trial.
- Subjects participating in this test must fill out the data with sincerity and honesty.

4. Methodology

This study was conducted in a temperature and humidity controlled area (indoor temperature $22\pm 2^{\circ}\text{C}$, humidity $50\pm 5\%$) within the HUMAN Co., Ltd. Skin Clinical Trial Center.

4.1. Materials to conduct the study

- 1) Finn Chamber[®] on Scanpor[®] (SmartPractice[®], U.S.A.)
- 2) Microman M100 (Gilson, France)
- 3) Micropore tape (3M/ Medical-Surgical Division)
- 4) Marking pen (Skin marker Slim, Sweden)

4.2. Test method and test site

Test site was located on the subject's back, avoiding the spine area and any area with skin discoloration or any lesion. The test was conducted on 34 healthy female adult subjects aged 20 years or older. 20 μl of test products were applied on the patch chamber and patches were fixed to the test area for 24 hours. The skin reaction was assessed 30 minutes and 24 hours after the patch was removed.

4.3. Evaluation procedure

Table 3. Evaluation procedure

Actions	Day 1	Day 2	Day 3
Admission of the subjects by the investigator	√	-	-
Application of the investigational product and giving the subjects constraints of the study	√	-	-
Remove the patch	-	√	-
Observation of test site after 30 min of the patch removal	-	√	-
Observation of test site after 24 hrs of the patch removal	-	-	√

4.4. Determination of irritation

The index of skin irritation was calculated based on guidelines proposed by Frosch & Kligman and CTFA guidelines (2007), and then the degree of skin irritation of the test product was evaluated using the skin irritation index of the Draize method (Table 4, 5, Fig 1).

Table 4. Skin Irritation Evaluation Criteria

Mark	Grade	Description
-	0	No reaction
+	1	Slight erythema, either spotty or diffuse
++	2	Moderate uniform erythema
+++	3	Intense erythema with edema
++++	4	Intense erythema with edema & vesicles

Fig 1. Skin Irritation Index Formula

$$\text{Skin Irritation Index} = \frac{\left[\left(\frac{\sum_{i=1}^n \text{Evaluation Value}}{n(\text{Number of Test Subjects})} \right) 30\text{min} + \left(\frac{\sum_{i=1}^n \text{Evaluation Value}}{n(\text{Number of Test Subjects})} \right) 24\text{hrs} \right]}{m(\text{Number of times evaluated})}$$

Table 5. Result Determination Table of Skin Patch Test

Primary Irritation Index	Irritation Evaluation
0.00 ~ 0.25	No irritation (Excellent)
0.26 ~ 1.00	Mild irritation (Good)
1.01 ~ 2.50	Medium irritation (Bad)
2.51 ~ 4.00	Strong irritation (Very Bad)

4.5. Evaluation of skin adverse event

The researchers monitored for any adverse skin reactions during the test period and reviewed the use of concomitant medications that could possibly affect the test. In the event of a negative reaction, the researchers will promptly inform the study director who will then take necessary measures and determine whether to proceed with involvement after verification.

5. Results

5.1. Results of skin primary irritation test

Dermatologist conducted a visual evaluation 30 minutes and 24 hours after removing the patch. As a result, the investigational product [GLUTANEX Glow Sun Cream Light] was classified as non-irritating (Excellent) range for human skin primary irritation (Table 6).

Table 6. Results of skin primary irritation test

No.*	Name of the product	30 min†				24 hrs‡				Skin Irritation Index	Irritation Evaluation
		1	2	3	4	1	2	3	4		
C-7	GLUTANEX Glow Sun Cream Light	-	-	-	-	-	-	-	-	0.00	No irritation (Excellent)

*Location on the application of the product

†30 min after removal of the patch

‡24 hours after removal of the patch

5.2. Evaluation result of skin adverse event

No adverse reactions or observed concomitant medication use were reported or observed during the study period.

6. Conclusion

Primary irritation human application test using a skin patch was performed to evaluate the safety of the [GLUTANEX Glow Sun Cream Light] requested by NEXUS PHARMA CO., LTD. by measuring the irritation index on the human skin.

1. Subjects

Final Number of Subject (Average age): 34 females (56.79 yrs)

2. Test Results

This test product showed a skin irritation index of 0.00.

3. There were no reports of any specific adverse skin reactions during the period when the test subjects used the test product, and no abnormal findings were observed in the physical examination by the dermatologist.

[GLUTANEX Glow Sun Cream Light] requested by NEXUS PHARMA CO., LTD. was considered a non-irritating product in terms of primary skin irritation test.

7. References

- 1) Guidelines for test methods for demonstrating cosmetic mark advertising, Ministry of Food and Drug Safety. 2014.
- 2) Guidelines for cosmetic clinical and efficacy examination, Ministry of Food and Drug Safety. 2012.
- 3) Basketter DA, Chamnerlain M, Griffiths HA, Rowson M, Whittle E, York M. The classification of skin irritants by human patch test. *Food Chem Toxicol.* 1997;37(8): 845-52.
- 4) CTFA Safety Testing Guideline: The Cosmetic, Toiletry and Fragrance Association, Inc. Washington, D.C. 1981:20005.
- 5) CTFA Safety Testing Guideline: The Cosmetic, Toiletry and Fragrance Association, Inc. Washington, D.C. 1991:20036.
- 6) Devos SA, Van Der Valk PG. Epicutaneous patch testing. *Eur J Dermatol.* 2002;12(5): 506-13.
- 7) Draize J.H., Woodard G., Calvery H.O. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. *J. Pharm. Exp. Ther.* 1994;82:377-390.
- 8) Draize J.H. *Dermal Toxicity Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics*, Association of Food and Drug Officials of the United States, Austin, Tex, USA. 1959.
- 9) Electrical impedance applied to non-invasive detection of irritation in skin. *Contact dermatitis.* 1992;27:37-42.
- 10) Fischer T, Maibach H. Finn chamber patch test technique. *Contact dermatitis.* 1984; 11(3):137-140.
- 11) Frosch P. J. & Kligman A.M. The soap chamber; a new method for assessing the irritancy. *J. Invest. Dermatol.* 1979;40:11-14.

8. Appendix

Appendix 1. Subject Test Guideline Document and Compensation Policy for Participants

A manual for the consent of the subject

Conformity Test by Skin Cohesion of '63 Test Samples'

The decision to participate in this study is up to you, and everything is up to you to decide to participate or give up according to your free will. The information below is information on this human application test and is designed to explain the contents of this human application test and your role and research process if you participate in this study. After you have enough time to review and read it, you can consult with your family or others. If you have any questions, please contact the research manager or test manager and decide whether to participate in the test.

1. Purpose and Method of Human Application Test

Human Co., Ltd. Skin Clinical Trial Center would like to conduct a human application test of 63 test samples.

- 1) This test aims to check the primary irritation caused by skin adhesion for adult men and women over the age of 20.
- 2) The test product is used in the back, and the primary stimulation of the product is evaluated before and after use.
- 3) A total of more than 30 subjects participate in the test, and they visit three times in three days, and each visit takes about 30 to 60 minutes.

2. Information on test products

The test product is cosmetics, which are removed after 24 hours of patch.

3. What you need to comply with

This matter must be observed for the purpose of protecting the subject and ensuring accurate research.

- 1) Please keep the schedule for use and inspection of the human body application test products.
- 2) While using the test product, please report it in detail to the research director or test person before using the drug or other product.
- 3) If you experience any adverse reactions while using the test product, please contact the research manager or test manager immediately and follow the instructions. If you need to undergo further testing, you should visit the Human Dermatology Department or the main center for testing.
- 4) Prohibits the use of products or medicines that may exhibit the same or similar effect as test products during testing.
- 5) Please avoid excessive UV exposure, skin care, massage, plastic surgery, vacation to other climatic areas, and stress while using test products.
- 6) The information obtained through this test must be kept confidential until the end of the test.

4. Adverse reactions or side effects predicted by participation in the human body application test

While participating in this test and using cosmetics, irritable skin may have unexpected risks such as stinging, rash, irritation, erythema, human face, swelling, etc. Therefore, when information on safety and side effects is collected during the human body application test, we will provide the information to the subject or legal representative in a timely manner.

5. Restrictions on Participation in Human Application Examinations

In this test, the case of pregnant women, or pregnant women who do not have an appropriate contraceptive plan or pregnant women who do not do appropriate contraception test methods.

6. Matters provided when participating in human application test

By participating in this examination and inconvenience products generated by participating in this examination, and inconvenience for time loss and inconvenience incurred due to the test participation. However, if you voluntarily withdraw the planned test or visit the planned test, separate transportation fee will not be paid to test before the test participation.

7. An expected profit

There are no expected therapeutic benefits even if you participate in this clinical trial.

8. In the event of damage related to the human body application test, compensation/compensation or treatment methods

Among this test period, researchers will try best to protect your safety and minimize response to your safety when a significant reaction occurs and appropriate measures. If damage occurs in relation to human application test, Andaba company will compensate in accordance with this center, will be compensated in accordance with this center.

9. Withdrawal after consent to participate in the human body application test

This test is voluntary participation by yourself, and you can always withdraw participation if you wish to discontinue it. If you wish to withdraw participation, please contact our examiners at this center.

10.A secret security guarantee

All records of your personal information obtained during the course of this exam will be confidential. As a result of this examination, your personal information will remain confidential even if the photographs and related data are published for the purpose of thesis and advertising. In addition, all records related to this examination will be preserved for three years from the end of this study.

11. Collecting and utilizing personal information

Your personal information (name, phone number, address, date of birth, gender, test information) will be used for the purpose of identifying the subject and conducting this test. The collected personal information, along with the test-related documents, will be stored in a place where access is restricted in accordance with the test-related laws and internal regulations of the test laboratory, and discarded. You have the right to refuse consent to collect and use personal information and to provide it to a third party, and if you do not consent, you cannot participate in the test.

12. Sign

Once you have answered all the questions you are curious about and have decided that you would like to participate in this test, you can sign a separate consent form for participation in the Human Application Test.

13. Contact Information

If you have any further information about this exam, any damage related to the exam, or need contact, you may have a telephone interview or consultation with the following research officers and examiners.

Sortation	Name	Tel.
Research director	Wonkyu Hong	+82-10-9651-3555
Investigator	Jiyeon Yun	+82-70-4680-0158

Appendix 2. Subjects' information

No.	Initial	Age	Gender
01	KOR	67	F
02	BJH	61	F
03	LSY	56	F
04	HSJ	67	F
05	KMS	59	F
06	PJY	47	F
07	GPK	55	F
08	GSO	64	F
09	PSJ	57	F
10	LSJ	54	F
11	SSH	64	F
12	LSK	54	F
13	SHS	50	F
14	KEJ	46	F
15	PGS	57	F
16	LHS	51	F
17	LKM	49	F
18	KEH	41	F
19	JYH	55	F
20	PJH	49	F
21	BSY	51	F
22	BMS	69	F
23	SYS	66	F
24	LTY	62	F
25	YKH	59	F
26	LHS	68	F
27	KMH	59	F
28	KSS	59	F
29	JJS	66	F
30	YJS	65	F
31	YJH	58	F
32	BMV	47	F
33	UJS	56	F
34	LCY	43	F

Appendix 3. Data of patch test result

Control No.	GLUTANEX Glow Sun Cream Light	
	30 minutes after removal	24 hours after removal
01	0	0
02	0	0
03	0	0
04	0	0
05	0	0
06	0	0
07	0	0
08	0	0
09	0	0
10	0	0
11	0	0
12	0	0
13	0	0
14	0	0
15	0	0
16	0	0
17	0	0
18	0	0
19	0	0
20	0	0
21	0	0
22	0	0
23	0	0
24	0	0
25	0	0
26	0	0
27	0	0
28	0	0
29	0	0
30	0	0
31	0	0
32	0	0
33	0	0
34	0	0

**0-No reaction, 1-Slight erythema, either spotty or diffuse, 2-Moderate uniform erythema, 3-Intense erythema with edema, 4-Intense erythema with edema & vesicles*

Institutional Assessment Report

■ Clinical Trials Information			
Name	Human Co., Ltd. Skin Clinical Trial Center		
Address	1516~1517ho, 62, Digital 31-gil, Guro-gu, Seoul, Republic of Korea		
President	Huijeong Jeong		
Principal Investigator	Wonkyu Hong / Dermatologist		
Phone Number	070-5222-9663	Fax	070-7500-9650
E-mail	skin@humantest.co.kr		
■ Objectives of the Clinical Trials Center			
This institution was established to perform human clinical studies on skin products to assess their safety, efficacy, and functionality. It also provides the results of these studies and relevant technical information			
■ Clinical Trials Items			
Cosmetic Safety Evaluation and Research		Evaluation and Research of functional Cosmetic	
Cosmetic Efficacy Evaluation and Research		Evaluation and Research of Quasi-Drugs	
Evaluation and Research of Skin-related Products		Evaluation and Research of Functional Foods	
■ Facility			
A thermo-hygrostat	VECTRA XT	Mark-Vu	
F-ray	DSLR (Cannon EOS 80D)	Antera 3D	
DUB® SkinScanner	Epsilon E100	Electronic scale	
Cutometer® dual MPA 580	Corneometer® CM825	Sebumeter® SM815	
Tewameter TM300	VISIA-7	PRIMOS CR	
Moisturemeter D	Vapometer	SkinGlossMeter	
SkinColorCatch	Skin pH meter	FLIR E75	
Kong Camera	Dino-Lite Digital Microscope	Folliscope 5.0	
Fine dust injection system	Infrared Moisture Analyzer	Bathtub	
Infrared Sauna System	IR lamp	Black D-Squame	
Static meters	Ballistometer BLS780	Clean bench	
Incubator	Auto clave	Water Purification System	
DERMAVISION Beauty Edition	MulteTest-dV	3D Meta-Vu	
UV-PCL 1000	EM-30P	-	

Research Resume

■ President

Huijeong Jeong / CEO

Education	2004	Graduated from Department of Environmental Engineering, Konkuk University, bachelor of engineering
Career	2018 ~ 2020	Head of Skin Clinical Trial Center, OATC Co., Ltd.
	2020 ~ present	CEO of Human Skin Clinical Trial Center

Reliability review of whitening function evaluation using transparent film mapping
 Blue light blocking test device patent registration[10-2346709]
 Patent registration of anti-dust performance test device and method[10-2019883]
 Patent application for portable cosmetic container[10-2019-0052712]
 Patent application for cosmetics sterilizer[10-2019-0080854]
 Patent application for cosmetic container with temperature control[10-2019-0084935]
 Patent application for skin heavy metal measuring device[10-2019-0168852]
 Cereal skin type analysis and patent application for customized cosmetics manufacturing device[10-2020-0068940]

■ Principal Investigator

Wonkyu Hong / Dermatologist

Education	2004	Graduated from Inha University School of Medicine, Bachelor of Medicine
	2004 ~ 2005	Intern of Inha University Hospital
	2005 ~ 2009	Resident of Inha University Hospital
	2007	Graduated from Inha University School of Medicine, Master of Medicine
Career	2004	Acquired Doctor's License (License number: 83931)
	2009	Acquired dermatologist (License number: 1771)
	2009 ~ 2012	Associate Chairman of Hansen Welfare Association Jeonbuk Branch
	2013 ~ 2015	Representative Director of Pyeongtaek Human Dermatology
	2013 ~ present	Adjunct Professor of Dermatology Class, Inha University
	2016	Representative Director of Cheongna Human Dermatology
	2018	Research Director of Human Cosmetic
	2018	Adjunct Professor of International St. Mary's Hospital
	2018 ~ 2020	Research Director of Skin Clinical Trial Center, OATC Co., Ltd.
	2020 ~ present	Research Director of Human Skin Clinical Trial Center
Society activities		Regular member of Korean Society of Dermatology
		Regular member of the Korean Society for Acne Research
		Regular member of Korean Hair Research Society
		Regular member of Association of Korean Dermatologists
	2018 ~ present	Intelligence member of Association of Korean Dermatologists
	2018 ~ present	Planning policy member of Association of Korean Dermatologists

■ Quality Assurance

Hongsuk Kim / Dermatologist

Education	2001	Graduated from Dong-A University College of Medicine, Bachelor of Medicine
	2001 ~ 2002	Intern of Dong-A University Hospital
	2002 ~ 2006	Resident of Dong-A University Hospital
	2004	Master of Dermatology, Dong-A University College of Medicine, Master of Medicine
Career	2001	Acquired Doctor's License(License number: 72561)
	2006	Acquired dermatologist (License number: 1629)
	2006 ~ 2009	Manager, Jeju Special Self-Governing Province Branch, Korea Hansen Welfare Association
	2010 ~ 2011	Manager of Nohyung Beautiful Dermatology
	2011 ~ 2012	Representative Manager of Dermatology, Seoul Clinic
	2014 ~ present	Adjunct Professor of Dermatology Class, Dong-A University,
	2012 ~ present	Representative director of Wine Dermatology Plastic Surgery
	2015 ~ present	Clinical Instructor of Department of Medical Beauty, Chungcheong University
	2016 ~ present	Clinical Instructor of Cosmetics Consulting Professional Association
	2020 ~ present	Human Skin Clinical Trial Center Reliability assurance officer
Society activities		Publication director of the Korean Society for Anti-aging Dermatology Director of the Korean Society for Skin Type Research Director of the Korean Society of Cosmetics and Cosmetology Regular member of Korean Society of Dermatology Regular member of Korean Society of Dermatology Surgery Regular member of Korean Medical Society for Cosmetics Regular member of Korean Laser Society Regular member of the Korean Society for Psoriasis Regular member of the Korean Society for Acne Research Regular member of Korean Society of Vitiligo Regular member of the Korean Atopic Dermatitis Association

■ Investigator

Hyoungsoon Hwang / Clinical Trial Division Head

Education	2000 ~ 2006	Yonsei University, Biological sciences, Bachelor of Science
Career	2007 ~ 2014	Researcher / DERMAPRO Ltd
	2014 ~ 2020	Senior researcher / GFC Life Science, KDRI
	2020 ~ 2022	Senior researcher / KSRC Korean Skin Research Center
	2023 ~ present	Human Skin Clinical Trial Center, Clinical Trial Division Head

Soyeon Kim / Senior Researcher

Education	2013 ~ 2015	Shin Ansan University, Department of Food and Life Sciences
Career	2015 ~ 2021	DERMAPRO Ltd. Researcher
	2021 ~ present	Human Skin Clinical Trial Center, Clinical Trial Team, Senior Researcher

Eunseok Lee / Senior researcher

Education	2009 ~ 2011	Shin Ansan University
	2018	Academic Creditbank System, business administration
Career	2011 ~ 2021	Dermapro Skin Research Center, Chief researcher
	2021 ~ present	Human Skin Clinical Trial Center, Clinical Trial Team, Senior researcher

Boram Heo / Senior researcher

Education	2017 ~ 2020	Konkuk University Future Knowledge Education Center, Department of K-beauty Industrial Convergence, Bachelor of Science
Career	2017 ~ 2019	Korea Institute of Dermatological Sciences, researcher
	2019 ~ 2022	P&K Skin Research Center, researcher
	2022 ~ 2024	Human Skin Clinical Trial Center, Clinical Trial Team, Senior researcher
	2024 ~ 2025	Ace Skin Clinical Research Institute, Senior researcher
	2025 ~ present	Human Skin Clinical Trial Center, Clinical Trial Team, Senior researcher

Daehan Lee / Senior researcher

Education	2017 ~ 2019	Eulji University Graduate School, Department of Medicine (Pharmacology), Master of Medical Science
Career	2019 ~ 2020	METACURA Ltd. Researcher
	2020 ~ 2022	PRIMORIS Ltd. Cell Research Team, Researcher
	2022 ~ 2024	NanoEntek Ltd. R&D Team, Manager
	2025 ~ present	Human Skin Clinical Trial Center, Clinical Trial Team, Senior researcher

Suyeong Kim / Chief researcher

Education	2013	Jeju National University Graduate School, Department of Chemistry, Master of Sciences
Career	2014 ~ 2022	Ami cosmetic, Research Engineer
	2022 ~ 2022	Chief researcher / KSRC Korean Skin Research Center
	2023 ~ present	Human Skin Clinical Trial Center, Chief researcher

Heejin Lim / Chief researcher

Education	2017 ~ 2021	Kyungsoong University, chemistry department, Bachelor of Science
Career	2021 ~ present	Human Skin Clinical Trial Center, Clinical Trial Team, Chief researcher

Sangmin Lee / Chief researcher

Education	2018 ~ 2020	Shin Ansan University, Department of Food and Life Sciences
	2022 ~ 2024	Korea National open University, Bachelor of Food and Nutrition
Career	2020 ~ 2023	COREDERM Inc, Skin Research Center, Researcher
	2024 ~ 2024	KC Skin Research Center, Chief Researcher
	2024 ~ present	Human Skin Clinical Trial Center, Clinical Trial Team, Chief researcher

Dahyeon Kim / Chief Researcher

Education	2018 ~ 2022	Bucheon University, Department of Beauty Care
Career	2022 ~ 2023	OATC Skin Clinical Test Center, Researcher
	2023 ~ present	Human Skin Clinical Trial Center, Clinical Trial Team, Researcher

Suji Lee / Researcher

Education 2018 ~ 2020 Shin Ansan University, Department of Food and Life Sciences

Career 2020 ~ 2023 COREDERM Inc, Skin Research Center, Researcher
2024 ~ present Human Skin Clinical Trial Center, Clinical Trial Team, Researcher

Jin Kim / Researcher

Education 2020 ~ 2024 U1 University, Department of beauty Care Engineering
2024 ~ present Konkuk University Graduate School of Industry Major in Cosmetology

Career 2023 ~ 2024 Korea Institute of Dermatological Sciences, Researcher
2024 ~ present Human Skin Clinical Trial Center, Clinical Trial Team, Researcher

Yesol Lee / Researcher

Education 2015 ~ 2017 Jaeneung University, Department of Cosmetics Science

Career 2024 ~ present Human Skin Clinical Trial Center, Clinical Trial Team, Researcher

Jiyu Kim / Researcher

Education 2020 ~ 2022 Jaeneung University, Department of Cosmetics Science

Career 2024 ~ present Human Skin Clinical Trial Center, Clinical Trial Team, Researcher

Eunjeong Kwon / Researcher

Education 2008 ~ 2010 Keimyung College University, Department of Beauty Coordination

Career 2024 ~ present Human Skin Clinical Trial Center, Clinical Trial Team, Researcher

Hyein Kim / Researcher

Education 2015 ~ 2019 Daegu University, Department of Food Engineering

Career 2024 ~ present Human Skin Clinical Trial Center, Clinical Trial Team, Researcher

Tao Gu / Researcher

Education 2014 ~ 2021 Dongui University, Department of Chemical Engineering

Career 2024 ~ present Human Skin Clinical Trial Center, Clinical Trial Team, Researcher

Hyoju Kim / Researcher

Education 2017 ~ 2022 Sangmyung University, Department of Green Chemical Engineering

Career 2024 ~ present Human Skin Clinical Trial Center, researcher

Doyun Jeong / researcher

Education 2018 ~ 2023 Jeju National University, Department of Earth and Marine Sciences

Career 2024 ~ present Human Skin Clinical Trial Center, Researcher

Shinhee Kang/ Researcher

Education 2020 ~ 2022 Konkuk University, Graduate School of Engineering
Department of Cosmetology

Education 2023 ~ 2025 Konkuk University, Graduate School of Department of
Cosmetics Engineering

Career 2025 ~ present Human Skin Clinical Trial Center, researcher



Yejin Kim / Senior Researcher

Education	2013 ~ 2017	Seowon University Graduate School of Industry of Cosmetics Engineering
	2018 ~ 2022	Seowon University, Bachelor of Science in Department of Cosmetics Engineering
Career	2016 ~ 2020	P&K Skin Research Center, Assistant Research Engineer
	2020 ~ 2022	Seowon Skin Research Center, Senior Researcher
	2022 ~ 2023	AllLive Clinical trial Research Center, Senior Researcher
	2023 ~ present	Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Senior Researcher

Subin Lee / Chief researcher

Education	2014 ~ 2018	Kongju University Department of Chemistry Education, Bachelor of Science
Career	2022 ~ 2024	P&K Skin Research Center, Researcher
	2025 ~ present	Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Chief researcher

Kyungeun Kim / Researcher

Education	2019~2020	Osan University, Beauty and Cosmetics Affiliation Department of Skin and Cosmetics
	2021 ~ 2023	Mokwon University, Department of Cosmetics Engineering, Bachelor of Science
Career	2022 ~ present	Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Researcher

Jieun Kim / Researcher

Education	2018 ~ 2022	Mokwon University, Department of Cosmetics Engineering
Career	2022 ~ present	Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Researcher

Hajeong Nam / Researcher

Education	2013 ~ 2016	Shinsung University, Department of Hotel Cooking associate degree
	2022 ~ present	Konkuk University Future Knowledge Education Center, Department of K-beauty Industrial Convergence, Bachelor of Science
Career	2022 ~ present	Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Researcher

Nayoung Lee / Researcher

Education	2018 ~ 2020	Incheon jaeneung University, Department of Cosmetics P&K Skin Research Center, Researcher
Career	2020 ~ 2024 2025 ~ present	Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Researcher

HyeonJi Lee / Researcher

Education	2020 ~ 2024	Daejeon University, Department of Beauty Design
Career	2024 ~ present	Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Researcher

Semin Choi / Researcher

Education	2018 ~ 2022	Dona-A University, Department of Chemistry
Career	2024 ~ present	Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Researcher

Minjin Lee / Researcher

Education	2018 ~ 2023	Andong University, Department of Pharmacognosy
Career	2024 ~ 2024 2024 ~ present	True Skin Clinical Trial Center, Clinical Trial Team, Researcher Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Researcher

Jongmin Kim / Researcher

Education	2013 ~ 2018	Chosun College Of Science & Technology, Department of Chemical Engineering
Career	2024 ~ present	Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Researcher

Eunbi Han / Researcher

Education	2020 ~ 2024	CHA University, Department of Bio Engineering
Career	2024 ~ present	Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Researcher

Yeonhee Jeong / Researcher

Education	2019 ~ 2023	Konkuk University glocal campus, Department of energy materal
Career	2023 ~ 2024 2024 ~ present	Cellontech, quality control team Human Skin Clinical Trial Center, Clinical Trial Team, Researcher

Jiyeon Yun / Researcher

Education	2019 ~ 2023	Daegu Hanny University, Department of Aroma-applied Industry and Industry of Cosmetics Engineering
Career	2024 ~ present	Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Researcher

Minkyoung Seo / Researcher

Education	2018 ~ 2023	Jeju National University, Department of chemistry and Cosmetics
Career	2024 ~ present	Human Ethic Skin Clinical Trial Center, Clinical Trial Team, Researcher

SangJune Park / Researcher

Education	2017 ~ 2019	Eulji University, Master of Medicine (microbiology, immunology)
Career	2021 ~ 2022	Sphebio researcher
	2023 ~ 2024	Asan medical center researcher
	2025 ~ present	Human Ethic Clinical Trial Center, researcher



List of publications

■ Principal investigator

No.	Journal
1	Bohee Yang, Wongyu Hong, Sunghyup Han, Jiwon Byeon, Heejin Song, Seunggyun In, Kwangsung Choi, Jeonghyun Shin. Skin Granulomas associated with Common Variable Immunodeficiency. Journal of Korean Society of Dermatology. 2011;49(7):601-605
2	Heejin Song, Sunghyup Han, Jiwon Byeon, Wongyu Hong, Hyunsook Lee, Jeonghyun Shin, Kwangsung Choi. Sodium Tetracycl Sulfate 3 Cases of Mucosal Cyst treated with Sclerotherapy. Journal of Korean Society of Dermatology. 2008;46(9):1249-1252
3	Sunghyup Han, Heejin Song, Wongyu Hong, Hyunsook Lee, Jeonghyun Shin, Kwangsung Choi. A Case of Sister Mary Joseph node. Journal of Korean Society of Dermatology. 2008;46(8):1103-1107
4	Heejin Song, Wongyu Hong, Hyunsook Lee, Jeonghyun Shin, Sunyoung Moon, Kwangsung Choi. A Case of Pregnant Woman Tsutsugamushi Disease treated with Azithromycin. Journal of Korean Society of Dermatology. 2008;46(6):859-861
5	Wongyu Hong, Jeonghyun Shin, Kwangsung Choi. Effect of Topical Treatment with Anthralin in Patients with Refractory Alopecia Areata having a Wide Range of Hair Loss. Journal of Korean Society of Dermatology. 2008;46(5):641-647
6	Heejin Song, Sunghyup Han, Wongyu Hong, Hyunsook Lee, Kwangsung Choi, Jeonghyun Shin. A Case of Rheumatic Neutrophil Dermatitis. Journal of Korean Society of Dermatology. 2008;46(4):514-516
7	Wongyu Hong, Jeonghyun Shin, Kwangsung Choi. Clinical Treatment Effect of Germinated Brown Rice Phellinus linteus in Atopic Dermatitis. Korea Journal of Herbology. 2008;23(1):103~108
8	Heejin Song, Wongyu Hong, Hyunsook Lee, Kwangsung Choi, Jeonghyun Shin. A Case of Macular Amyloidosis Presented as Depressed Patches on the Face. Journal of Korean Society of Dermatology. 2008;46(2):285-288
9	Hyunsook Lee, Sunghyup Han, Heejin Song, Wongyu Hong, Jeonghyun Shin, Kwangsung Choi. A Case of Lichenoid Drug Eruption by Allopurinol. Journal of Korean Society of Dermatology. 2008;46(1);130-133

-
- 10 Wongyu Hong, Heejin Song, Hyunsook Lee, Jongrok Lee, Jeonghyun Shin, Kwangsung Choi. A Case of Cowen Syndrome. *Journal of Korean Society of Dermatology*. 2007;45(8);829-831
-
- 11 Hyeyoung Lee, Wongyu Hong, Jeonghyun Shin, Juyoung Noh, Jongrok Lee. A Case of Umbilical Omphalomesenteric Duct Polyp. *Journal of Korean Society of Dermatology*. 2006;44(11);1342-1344
-
- 12 Hyunsook Lee, Wongyu Hong, Jongrok Lee, Jeonghyun Shin, Kwangsung Choi, Yuchan Kim. A Case of Acrosyringial Nevus. *Journal of Korean Society of Dermatology*. 2006;44(6);751-753
-
- 13 Wongyu Hong, Hyunsook Lee, Jongrok Lee, Kwangsung Choi, Jeonghyun Shin, Yuchan Kim. 2 Cases of Pilomatricoma with Bullous Appearance. *Journal of Korean Society of Dermatology*. 2006;44(3);330-333
-
- 14 Hyunsook Lee, Wongyu Hong, Seunggyun In, Jongrok Lee, Jeonghyun Shin, Kwangsung Choi. A Case of Dermatomyositis Associated with Scarring Alopecic Patches. *Journal of Korean Society of Dermatology*. 2006;44(2);250-252
-
- 15 Wongyu Hong, Jeonghyun Shin, Kwangsung Choi. Effect of Anthralin Immunotherapy in Patients with Alopecia Areata having a Wide Range of Hair Loss. *Journal of Korean Society of Dermatology*. 2009;42(9);1130-1137
-
- 16 Heejin Song, Wongyu Hong, Sunghyup Han, Jiwon Byeon, Hyunsook Lee, Kwangsung Choi, Jeonghyun Shin. Acral Angioosteoma Cutis. *American Journal of Dermatopathology*. 2010;32(5);477-478
-
- 17 Heejin Song, Sunghyup Han, Wongyu Hong, Hyunsook Lee, Jeonghyun Shin, Kwangsung Choi. Paraneoplastic bullous pemphigoid: Clinical disease activity correlated with enzyme-linked immunosorbent assay index for the NC16A domain of BP180. *Journal of Dermatology*. 2009;36:66-68
-
- 18 Jiwon Byeon, Sunghyup Han, Heejin Song, Wongyu Hong, Hyunsook Lee, Jeonghyun Shin, Kwangsung Choi. A case of supraumbilical skin rash after chemoembolization for hepatocellular carcinoma. *Journal of the European Academy of Dermatology and Venereology*. 2009;23(12);1458-1459
-
- 19 Wongyu Hong, Heejin Song, Hyunsook Lee, Jeonghyun Shin, Kwangsung Choi. Hobnail haemangioma associated with a secondary sexual characteristic. *Journal of the European Academy of Dermatology and Venereology*. 2009;23:465-466
-
- 20 Heejin Song, Wongyu Hong, Hyunsook Lee, Kwangsung Choi, Jeonghyun Shin. Herpes zoster complicated by delayed intracranial haemorrhage. *Clinical and Experimental Dermatology*. 2009;34:518-540
-

-
- 21 Sunghyup Han, Heejin Song, Wongyu Hong, Hyunsook Lee, Kwangsung Choi, Jeonghyun Shin. Rhabdomyomatous mesenchymal hamartoma of the vagina. *Pediatric Dermatology*. 2009;26(6):753-755
-
- 22 Sunghyup Han, Heejin Song, Wongyu Hong, Hyunsook Lee, Kwangsung Choi, Jeonghyun Shin. A case of adult blaschkitis with features of interface dermatitis. *British Journal of Dermatology*. 2008;159:231–266
-
- 23 Heejin Song, Wongyu Hong, Hyunsook Lee, Jeonghyun Shin, Kwangsung Choi. Intramuscular lipoma of the sternocleidomastoid muscle. *J Eur Acad Dermatol Venereol*. 2008;22:363–404
-
- 24 Hyunsook Lee, Heejin Song, Wongyu Hong, Jeonghyun Shin, Kwangsung Choi. Pseudoxanthoma elasticum-like papillary dermal elastolysis with solar elastosis. *J Eur Acad Dermatol Venereol*. 2008;22:363–404
-
- 25 Shingu Park, Uicheol Lee, Wongyu Hong, Heejin Song, Jeonghyun Shin. A Case of Occupational Allergic Contact Dermatitis due to PVC Hose. *Journal of Occupational Health*. 2008;50:197-200
-
- 26 Jeonghyun Shin, Wongyu Hong, Heejin Song, Kwangsung Choi, Yuchan Kim. Atypical Acute Graft-Versus-Host Disease. *American journal of dermatopathology*. 2007;29;576-577
-
- 27 Byun JW, Hong WK, Han SH, Song HJ, Lee HS, Choi GS, Shin JH. Red scrotum syndrome: successful treatment with oral doxycycline. *International Journal of Dermatology*. 2012;51(3):362-363
-

■ Quality Assurance

No.	Journal
1	Sentinel Lymph Node Biopsy and Staging of Melanoma Using Lymphoscintigraphy and Gamma-probe
2	Preference of Near-erythemogenic Narrow-band UVB Phototherapy in Psoriasis and Change of Dendritic Cells and Chemokines
3	Effectiveness of Amniotic Membrane Patch in the Treatment of Chronic Ulcers
4	Effects of Keratinocyte Growth Factor (KGF), Epidermal Growth Factor (EGF), and Extracellular Calcium on the Growth of Cultured Psoriatic Keratinocytes
5	Photodynamic Therapy of Actinic Keratoses Using 585nm Dye Laser and Variable Lights
6	A Clinical Analysis of the Risk Factors of Varicose Veins in Korean
7	A Case of Churg-Strauss Syndrome Associated with Small Bowel Perforation following High Dose Systemic Steroid Intravenous Injection
8	A Case of Multicentric Reticulohistiocytosis Misdiagnosed As Rheumatoid Arthritis
9	A Case of Pigmented Clear Cell Acanthoma
10	A Case of SAPHO Syndrome in a Palmoplantar Pustulosis Patient
11	A Case of Xanthoma Disseminatum with Diabetes Insipidus
12	A Case of Chilblain Lupus Erythematosus Associated with Antibodies to SSA/Ro
13	A Case of Primary Mucinous Carcinoma of the Skin
14	A Case of ALK-negative Systemic Anaplastic Large Cell Lymphoma
15	CD4-/CD56+/CD123+ Hematodermic neoplasm showing early liver metastasis

This report has not to be used for any purposes other than those permitted under "the Copyright Act" and "the Trade Secrets Act". Without the written consent of Human Co., Ltd. Skin Clinical Trial Center, neither the whole report nor any part of it may be transferred, accessed, cited, reproduced, transmitted, or disclosed.